Calculate VLDL cholesterol using Friedewald and Martin-Hopkins methods, compute non-HDL-C, remnant cholesterol, TG/HDL ratio for insulin resistance, and stratify triglyceride-related cardiovascular...
Very low-density lipoprotein (VLDL) cholesterol is the primary triglyceride-carrying lipoprotein in the fasting state, synthesized by the liver and progressively lipolyzed into intermediate-density (IDL) and ultimately low-density (LDL) lipoproteins. VLDL cholesterol is not typically measured directly in standard lipid panels but is estimated from triglycerides using the Friedewald formula (VLDL = TG/5) or the more accurate Martin-Hopkins method with TG-dependent adjustment factors.
This calculator computes VLDL cholesterol by three methods (Friedewald TG/5, Martin-Hopkins with adjustable factor, and direct subtraction from the full lipid panel), calculates non-HDL cholesterol (which captures all atherogenic particles including VLDL, IDL, LDL, and Lp(a)), estimates remnant cholesterol as an emerging cardiovascular risk biomarker, and computes the TG/HDL ratio as a validated surrogate marker for insulin resistance and small dense LDL particles.
Elevated VLDL contributes to atherosclerosis both through direct arterial wall deposition and through generation of atherogenic remnant particles and small dense LDL. The clinical significance of VLDL extends beyond cardiovascular risk: triglyceride levels above 500 mg/dL carry risk of acute pancreatitis through toxic free fatty acid release, making triglyceride-lowering an urgent priority independent of cardiovascular prevention.
This calculator provides three independent VLDL estimates, computes non-HDL cholesterol and remnant cholesterol, calculates the TG/HDL insulin resistance proxy, visualizes the lipid profile with target comparisons, and includes comprehensive reference tables for hypertriglyceridemia workup and treatment thresholds. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
VLDL (Friedewald) = Triglycerides ÷ 5 (mg/dL). VLDL (Martin-Hopkins) = TG ÷ adjustable factor (factor varies 5.0–8.5 based on TG level). VLDL (Panel) = TC − LDL − HDL. Non-HDL-C = TC − HDL. Remnant Cholesterol = Non-HDL-C − LDL ≈ VLDL + IDL. TG/HDL ratio (insulin resistance proxy).
Result: VLDL 70 (Friedewald), 50 (Martin-Hopkins), 85 (Panel). Non-HDL-C 215. TG/HDL 10.0 → high insulin resistance probability.
Multiple VLDL estimates converge on significantly elevated levels (>30 mg/dL). The very high TG/HDL ratio of 10.0 strongly suggests insulin resistance and metabolic syndrome. Non-HDL-C of 215 exceeds optimal (<130) by a wide margin, indicating high atherogenic burden.
Use consistent units, verify assumptions, and document conversion standards for repeatable outcomes.
Most mistakes come from mixed standards, rounding too early, or misread labels. Recheck final values before use. ## Practical Notes
Use this for repeatability, keep assumptions explicit. ## Practical Notes
Track units and conversion paths before applying the result. ## Practical Notes
Use this note as a quick practical validation checkpoint. ## Practical Notes
Keep this guidance aligned to expected inputs. ## Practical Notes
Use as a sanity check against edge-case outputs. ## Practical Notes
Capture likely mistakes before publishing this value. ## Practical Notes
Document expected ranges when sharing results.
VLDL is a triglyceride-rich lipoprotein made by the liver. It matters because elevated VLDL contributes to atherosclerosis both directly and through its metabolic products (remnants and small dense LDL). VLDL remnant particles are directly taken up by arterial macrophages, promoting plaque formation — unlike LDL, VLDL remnants do not require oxidation to be atherogenic.
The Friedewald formula (TG/5) assumes a fixed TG-to-VLDL ratio that holds well at TG <150 but becomes progressively inaccurate above 200 and is unreliable above 400 mg/dL. In hypertriglyceridemia, VLDL particles are more TG-enriched, so dividing by 5 overestimates VLDL cholesterol. The Martin-Hopkins method addresses this with a TG-dependent adjustment factor.
Non-HDL-C (TC minus HDL) captures all atherogenic lipoproteins — LDL, VLDL, IDL, and Lp(a). It is a stronger predictor of cardiovascular events than LDL alone, especially when triglycerides are elevated. The 2018 AHA/ACC guidelines recommend non-HDL-C as a secondary target, with goals 30 mg/dL above LDL targets.
The TG/HDL ratio is a validated surrogate marker for insulin resistance and small dense LDL particles. Ratios >3.5 strongly correlate with atherogenic dyslipidemia (small dense LDL, high VLDL, low HDL) characteristic of metabolic syndrome and Type 2 diabetes. It performs comparably to formal insulin sensitivity testing in epidemiologic studies.
Acute pancreatitis risk increases significantly when triglycerides exceed 500 mg/dL, with substantial risk above 1,000 mg/dL. The mechanism involves pancreatic lipase hydrolyzing excess triglycerides into free fatty acids, which are directly toxic to acinar cells. Acute management includes NPO, IV insulin (which activates lipoprotein lipase), and sometimes plasmapheresis.
Remnant cholesterol represents cholesterol carried by triglyceride-rich remnant particles (partially lipolyzed VLDL and IDL). It is estimated as Non-HDL-C minus LDL. Mendelian randomization studies show that remnant cholesterol is causal for coronary artery disease, with risk comparable to LDL cholesterol on a per-particle basis.